How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,855 results for

Imiquimod

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1721. Topical imiquimod in the treatment of infantile hemangiomas: a retrospective study. (Abstract)

Topical imiquimod in the treatment of infantile hemangiomas: a retrospective study. Active nonintervention remains the mainstay of therapy for most uncomplicated infantile hemangiomas (IH) because of their expected involution. Topical imiquimod, with its ability to induce the production of interferon, tumor necrosis factor-alpha, and the antiangiogenesis factor tissue inhibitor of matrix metalloproteinase, has been recently reported to be efficacious in the treatment of IH.We sought to evaluate (...) the efficacy of imiquimod 5% cream in the treatment of noncomplicated IH and possible side effects.A retrospective chart review analysis was performed in 18 children (16 girls and 2 boys) with a median age of 18 weeks (range: 4-256 weeks). A total of 22 hemangiomas (14 located on head, 3 on genitalia, 2 on trunk, and 3 on extremities) were treated with imiquimod 5% cream. Imiquimod was applied 3 times weekly in 10 patients and 5 times weekly in 8 patients for a mean duration of 17 weeks (7-46 weeks).All

2007 Journal of American Academy of Dermatology

1722. Erythroplasia of Queyrat treated with imiquimod 5% cream. (Abstract)

Erythroplasia of Queyrat treated with imiquimod 5% cream. Imiquimod is an immune response-modifying agent with potent antiviral and antitumor activity effective in the treatment of various skin disorders, including in situ carcinoma of the skin (Bowen's disease). The case of a 64-year-old man affected by an in situ carcinoma of the glans mucosa, namely erythroplasia of Queyrat, successfully treated with imiquimod 5% cream is described. Because the results of tests for human papillomavirus (...) infection were negative in this case, we suggest that imiquimod may have acted through an antitumor effect mediated by cytokine activation. This compound may represent an alternative treatment in patients with erythroplasia of Queyrat, although the dosing schedule and treatment duration require further evaluation.

2006 Journal of American Academy of Dermatology

1723. Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy. (Abstract)

Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy. Topical therapeutic options for cutaneous squamous cell carcinoma in situ include 5-fluorouracil cream and imiquimod cream. Such treatment may be preferable to surgical or destructive modalities in certain anatomic locations and in instances where patients are unwilling or poor surgical candidates. We present 4 such patients (...) with cutaneous squamous cell carcinoma in situ involving a digit. Each patient failed treatment with imiquimod cream as monotherapy. In addition, two patients failed treatment with 5-fluorouracil cream as monotherapy. All 4 responded completely to 5-fluorouracil and imiquimod cream as combination therapy. In patients who have failed monotherapy with a topical agent for cutaneous squamous cell carcinoma in situ, combination treatment using both topical 5-fluorouracil cream and imiquimod cream may

2006 Journal of American Academy of Dermatology

1724. Treatment of a patient with epidermodysplasia verruciformis carrying a novel EVER2 mutation with imiquimod. (Abstract)

Treatment of a patient with epidermodysplasia verruciformis carrying a novel EVER2 mutation with imiquimod. Epidermodysplasia verruciformis (EV) is a rare disorder characterized by widespread human papillomavirus infection and malignant transformation. EV may be caused by mutations of the genes EVER1 or EVER2, which are located on the EV1 locus, 17q25. We describe a patient with EV and a novel homozygous gene mutation of EVER2 gene who was treated successfully with topical imiquimod.

2007 Journal of American Academy of Dermatology

1725. Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma. (Abstract)

Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma. Imiquimod has been successfully used for treatment of various epithelial cutaneous neoplasms.Our aim was to evaluate the efficacy and tolerability of imiquimod 5% cream for treatment of Bowen's disease and invasive squamous cell carcinoma (SCC) in patients who were unsuitable candidates for surgery.Five Bowen's disease lesions and 7 invasive SCC lesions on 10 patients were treated with imiquimod once (...) sections.Topical application of imiquimod 5% cream might represent an alternative topical treatment to surgery in selected cases of Bowen's disease and invasive SCC.

2006 Journal of American Academy of Dermatology

1726. Basal cell carcinoma: treatment with imiquimod. (Abstract)

Basal cell carcinoma: treatment with imiquimod. Basal cell carcinoma (BCC) is the most common cutaneous malignancy. There are various approaches to its treatment, but imiquimod, the immune response modifier, offers a topical, noninvasive, nonsurgical therapeutic option.We present our experience of the treatment of 96 patients with BCCs during the period March 2002 to February 2004 at the Dermatology Department, Hospital Clínico S. Cecilio, Granada, Spain. One hundred and forty-one tumors (...) (nodular, superficial, and pearly/ulcerated clinical types) were treated with imiquimod.The clinical cure rate at 12 months was 80-85%.Our experience indicates that imiquimod is a reasonable option for the treatment of BCC. It is low cost, can be delivered via ambulatory care, and has tolerable side-effects.

2007 International Journal of Dermatology

1727. Imiquimod 5% cream for the prevention of recurrence after excision of presternal keloids. (Abstract)

Imiquimod 5% cream for the prevention of recurrence after excision of presternal keloids. Imiquimod 5% cream has been found to be effective and safe in preventing recurrence of keloids on earlobes after excision. We evaluated the efficacy and safety of imiquimod 5% cream in preventing the recurrence of presternal keloids after excision (3 keloids in 2 patients). After excision with radiofrequency, imiquimod 5% cream was applied once daily at bedtime for 8 weeks, and the defect was left to heal (...) by secondary intention. In all the treated keloids, the defect healed in 6-8 weeks, and no recurrence was seen while on imiquimod application; however, all keloids completely recurred within 4 weeks of stopping imiquimod. Side effects were mild and acceptable in the form of burning and pain. Imiquimod did exert an antifibrotic action but it was short-lived.2007 S. Karger AG, Basel

2007 Dermatology

1728. 5% topical imiquimod tolerance in transplant recipients. (Abstract)

5% topical imiquimod tolerance in transplant recipients. Topical imiquimod is a new immunomodulator agent approved for genital warts, actinic keratosis (AK) or carcinoma, occurring in immunocompetent patients.This study aimed to assess the safety and efficacy of imiquimod for the treatment of warts, AK and bowenoid papulosis (BP) in transplant patients.24 transplant patients (18 kidney, 4 kidney-pancreas and 2 heart) were included in this retrospective study conducted between June 2000 (...) and February 2003 at the department of dermatology of 3 hospitals. Imiquimod cream was applied 3 times a week over a median period of 9 weeks.Graft function was not altered under therapy. Local tolerance was excellent. Complete responses were observed in 1 patient (1/12) with cutaneous warts and 1 (1/6) with AK. Two patients of 3 with BP had total clearance of their lesions. Partial responses were observed in 3 of the 6 AK-treated patients, 5 of 12 patients with cutaneous warts and 1 of 2 patients

2007 Dermatology

1729. Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy. (Abstract)

Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy. Clinically amelanotic lentigo maligna often resembles an inflammatory lesion rather than a melanoma in situ. We present two cases of extensive amelanotic lentigo maligna presenting as gradually enlarging erythematous patches on the faces of women following incomplete excisions of lentigo maligna. Because of their site and size, therapeutic options were limited; the lesions have, however, resolved (clinically (...) and histologically) following the topical application of 5% imiquimod cream. We discuss the rationale for the use of imiquimod in the treatment of lentigo maligna.

2004 Journal of American Academy of Dermatology

1730. Clinical and histopathologic observations of the action of imiquimod in an epithelioid hemangioendothelioma and Paget's mammary disease. (Abstract)

Clinical and histopathologic observations of the action of imiquimod in an epithelioid hemangioendothelioma and Paget's mammary disease. An epithelioid hemangioendothelioma and Paget's disease of the breast were treated with topical imiquimod 5% cream with very impressive results. In both of the tumors complete disappearance of the lesions occurred. In this article, in addition to describing the treatment approach, the findings in biopsy specimens of the epithelioid hemangioendothelioma (...) and the Paget's disease before, during, and after therapy will be described. The histologic findings show ample evidence that there is both a lymphocytic T helper 1-like and T helper 2-like response from imiquimod. Direct evidence of lymphocytotoxicity was found. Furthermore, mast cells appear to be involved in the development of regression in the vascular tumor. Although the study is very limited and reports only two cases, the results are striking. We considered it important to describe these findings

2006 Journal of American Academy of Dermatology

1731. Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis. (Abstract)

Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis. Imiquimod, a potent immunomodulator, not having a direct antiproliferative activity, was found to be effective in genital and cutaneous premalignancies and malignancies. As tumor development depends on blood vessel supply, the inhibition of angiogenesis could be responsible for the antitumor activity.To find in a murine model whether imiquimod has antiangiogenic activity and whether this activity is mediated by locally induced (...) cytokines.The study was performed in two cell lines: Skv human keratinocytes containing multiple integrated copies of HPV16 derived from bowenoid papulosis, and murine L1 lung sarcoma cells of Balb/c mice. The murine model of cutaneous angiogenesis was used to assess and count the new blood vessel formation. The mice were immunosuppressed by a total body X-ray irradiation and treated with 5% or 2.5% imiquimod cream before or after induction of angiogenesis with intradermally injected tumor cell suspension

2005 International Journal of Dermatology

1732. Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream. (Abstract)

Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream. Current treatment recommendations for malignant melanoma in situ include surgical excision with at least 0.5 cm margins. On the head or neck, obtaining adequate surgical margins for melanoma can be challenging and often disfiguring. In addition, some elderly patients may not be good surgical candidates and may request less aggressive interventions.We report herein three cases of malignant melanoma in situ (...) on the face treated with topical imiquimod cream.Complete regression of malignant melanoma in situ was observed on treatment with 5% topical imiquimod cream. The varied treatment regimens, rationale for using imiquimod rather than performing surgery, and the possible mechanisms of action are discussed.Topical imiquimod can be used successfully for the treatment of malignant melanoma in situ on the face.

2005 International Journal of Dermatology

1733. Seborrheic keratoses: a study comparing the standard cryosurgery with topical calcipotriene, topical tazarotene, and topical imiquimod. (Abstract)

Seborrheic keratoses: a study comparing the standard cryosurgery with topical calcipotriene, topical tazarotene, and topical imiquimod. Patients with seborrheic keratoses frequently desire an effective topical therapy for seborrheic keratoses.To compare topical calcipotriene, topical tazarotene, and topical imiquimod with standard cryosurgery in the treatment of seborrheic keratoses.Fifteen patients with numerous seborrheic keratoses were enrolled in an open-label study comparing cryosurgery

2004 International Journal of Dermatology

1734. Successful treatment of perianal Bowen's disease with imiquimod. (Abstract)

Successful treatment of perianal Bowen's disease with imiquimod. Although perianal Bowen's disease (BD) is a relatively uncommon malignancy, it is being detected with increasing frequency. It has a strong tendency for local recurrence and treatment remains controversial. The effectiveness of different treatment modalities, ranging from aggressive wide local excision with skin grafting to the application of a topical immune response modifier, remains uncertain. To our knowledge only two cases (...) of perianal BD, successfully treated with imiquimod, have been reported. We wish to present the third case, effectively treated with imiquimod.

2007 International Journal of Dermatology

1735. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma. (Abstract)

Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma. Imiquimod is an immune-response modifier that has been shown to be effective in the treatment of superficial and nodular basal cell carcinoma (BCC). The objective of this open-label study was to investigate the effectiveness of imiquimod 5% cream in superficial, nodular, and infiltrative BCC. Fifty-five Caucasian patients with primary BCC measuring 8 mm or more in diameter with a superficial (...) , nodular, or infiltrative histological pattern were included in the study. Four groups of BCC (A, B, C, and D) and two dosing regimens were studied: 35 BCCs (groups A, B, and C) were treated with imiquimod three times weekly and 20 BCCs (group D) were treated with imiquimod five times weekly. Histological samples were obtained before treatment, during treatment (on day 22 in group A, day 15 in group B, and day 8 in groups C and D), and 6 weeks after treatment. All patients were followed-up

2004 Clinical & Experimental Dermatology

1736. Efficacy of imiquimod 5% cream for basal cell carcinoma in transplant patients. (Abstract)

Efficacy of imiquimod 5% cream for basal cell carcinoma in transplant patients. Imiquimod 5% cream has proven to be effective in superficial and nodular basal cell carcinomas in nonimmunosuppressed patients and treating squamous cell carcinomas in situ in transplant patients. The objective of this open-label study was to determine the efficacy of imiquimod 5% cream in treating basal cell carcinoma in transplant patients. At our unit, four renal transplant patients and one cardiac transplant (...) patient were diagnosed with 10 basal cell carcinomas in 2001. Four tumours were superficial, three nodular and three infiltrative. Five basal cell carcinomas received imiquimod 5% cream at night four times weekly for 6 weeks, without occlusion, and the other five tumours were treated on 5 nights per week for 5 weeks. Biopsies taken 6 weeks after the end of treatment showed no tumour in seven of 10 of the cases. Notably, all four superficial basal cell carcinomas, two of the three of nodular lesions

2004 Clinical & Experimental Dermatology

1737. Topical imiquimod immunotherapy in the management of lentigo maligna. (Abstract)

Topical imiquimod immunotherapy in the management of lentigo maligna. Melanoma in situ of the lentigo maligna (LM) type is a precursor lesion of LM melanoma. It most commonly occurs in elderly individuals, on the head and neck. Although surgical excision is recommended, this may not be practical for large lesions at cosmetically sensitive sites. In addition, histological changes commonly extend beyond the clinical margins of the lesion. This study describes the use of imiquimod 5% cream (...) as topical immunotherapy in the management of lentigo maligna. Twelve patients (average age 63 years, 10 female), of biopsy-proven facial LM were treated with topical imiquimod, three times a week for 6 weeks. In the absence of an inflammatory response, patients were asked to apply the treatment daily. Seven showed clearance of the LM clinically and histologically. A further three patients showed clearance histologically with persisting pigmentation due to dermal melanin and melanophages. Thus, 10 of 12

2004 Clinical & Experimental Dermatology

1738. A pilot study of treatment of lentigo maligna with 5% imiquimod cream. (Abstract)

A pilot study of treatment of lentigo maligna with 5% imiquimod cream. Lentigo maligna (LM) is an in situ form of malignant melanoma, and surgical excision is often unsatisfactory. Imiquimod cream is an immune response modifier and induces a predominantly T-helper 1 type response.Assessment of histological and clinical response of surgically resectable LM after treatment with 5% imiquimod cream.Six patients with LM were treated with 5% imiquimod cream daily for 6 weeks. The whole site (...) imiquimod cream merits further investigation as a new therapy for LM.

2004 British Journal of Dermatology

1739. Imiquimod cream 5% for recalcitrant cutaneous warts in immunosuppressed individuals. (Abstract)

Imiquimod cream 5% for recalcitrant cutaneous warts in immunosuppressed individuals. Viral warts may cause significant morbidity in individuals unable to mount an adequate T-helper 1 cell-mediated immune response to human papillomavirus. Imiquimod is a potent inducer of antiviral cytokine activity which has shown significant efficacy in the treatment of genital warts. Similar efficacy in cutaneous warts is not yet established.To assess the response of persistent cutaneous warts to 5% imiquimod (...) cream in immunosuppressed individuals.Fifteen immunosuppressed patients with warts on the hands and/or feet present for more than 18 months, which had failed to respond to a minimum of 12 weeks of topical salicylic acid and four cycles of cryotherapy, were recruited. Imiquimod 5% cream was applied in an open label, right vs. left comparison study for 24 weeks (three times weekly for 8 weeks, daily for 8 weeks, then daily with occlusion for 8 weeks).Twelve (80%) patients completed the study protocol

2005 British Journal of Dermatology

1740. In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases. (Abstract)

In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases. There is a growing body of evidence to support the efficacy of topical imiquimod in the treatment of primary skin carcinomas. Conflicting data exist concerning the use of imiquimod for the treatment of skin melanoma metastases. To date, only the impact of imiquimod on cytokines involved in immunological processes has been (...) studied extensively. We report a woman successfully treated with imiquimod (once daily for 8 weeks) for skin melanoma metastases in whom we investigated the expression of molecules involved in metastasis and angiogenesis. Before and after treatment, a skin lesion was biopsied and the expression of the following molecules was investigated using real-time reverse transcription-polymerase chain reaction: matrix metalloproteinase (MMP)-1, 2 and 9 and their inhibitors KiSS-1 and tissue inhibitor

2004 British Journal of Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>